Highlights
- A pilot study with 39 participants found that just 15 minutes of NanoVi® therapy significantly improved autonomic balance.
- Parasympathetic activity (RMSSD) increased by 19.4%, indicating enhanced recovery potential.
- Stress Index decreased by 45.7%, suggesting reduced sympathetic (“fight-or-flight”) activation.
- Autonomic coordination (Alpha-1) improved by 4.5%, reflecting better nervous system regulation.
- Results support NanoVi®’s potential to promote relaxation, stress resilience, and performance recovery through natural autonomic modulation.
The autonomic nervous system (ANS) regulates many essential body functions, maintaining a delicate balance between the sympathetic (“fight or flight”) and parasympathetic (“rest and digest”) branches. When this balance is disrupted, it can lead to elevated stress, slower recovery, and diminished performance. Heart rate variability (HRV) is a well-established measure for assessing autonomic balance and nervous system resilience.
A recent pilot study explored whether a single 15-minute session with the NanoVi® device could influence HRV markers related to parasympathetic activity, stress response, and overall autonomic coordination.
Thirty-nine participants completed HRV assessments before and after one NanoVi® session.
Three key HRV indicators were evaluated:
- RMSSD – an indicator of parasympathetic tone
- Stress Index – a measure of sympathetic activation
- Alpha-1 (DFA 1) – a marker of overall autonomic coordination
Results were compelling:
- Parasympathetic activity (RMSSD) increased by 19.4% (p < 0.0001)
- Stress Index decreased by 45.7% (p < 0.0001)
- Autonomic coordination (Alpha-1) improved by 4.5% (p = 0.0006)
These findings suggest that even a brief NanoVi® session can meaningfully enhance parasympathetic activation, reduce sympathetic overactivity, and improve autonomic regulation. This indicates potential applications for stress reduction, recovery, and performance optimization, while emphasizing the need for future long-term research to confirm these promising results.
This study was conducted using the NanoVi Exo® device, manufactured by Eng3 Corporation
Contact info: +1 206 525-0227
Eastlake Ave E Seattle, WA 98102
info@eng3.com
Figure 1. Change in RMSSD (Parasympathetic Activity) Before and After NanoVi®. RMSSD, a marker of parasympathetic activity, increased significantly by 19.4% (14.19 to 16.95, p = 0.0001, Wilcoxon matched-pairs signed-rank test). Error bars represent the standard error of the mean (SEM).
Figure 2. Change in Stress Index (Sympathetic Activity) Before and After NanoVi®. The Stress Index, a marker of sympathetic nervous system activity, decreased significantly by 45.7% (403.74 to 201.22, p < 0.0001, Wilcoxon matched-pairs signed-rank test). Lower SI values indicate reduced sympathetic dominance and improved autonomic balance. Error bars represent the standard error of the mean (SEM).
Figure 3. Change in Alpha-1 Value (Autonomic Regulation) Before and After NanoVi®. The Alpha-1 value, which reflects the quality of autonomic regulation and coordination, increased by 4.5% (1.323 to 1.384, p = 0.0495, Wilcoxon matched-pairs signed-rank test), suggesting improved autonomic adaptability and resilience. Error bars represent the standard error of the mean (SEM).
Link to full paper: Read here